What does CUSIP 04962H506 represent in this 13F holders report?

CUSIP 04962H506 is the security identifier for ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock used to aggregate holder disclosures.

How many institutions held ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock in Q2 2019?

8 institutional investors reported ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock for Q2 2019. Use the holders table for investor-level position and value details.

ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS)

CUSIP: 04962H506

Q2 2019 13F Holders as of 30 Jun 2019

Type / Class: Equity / Common Stock
Shares outstanding: 129,337,627
Total 13F shares: 253,600
Share change: -53,338
Total reported value: $647,150
Price per share: $2.55
Number of holders: 8
Value change: -$201,112
Number of buys: 4
Number of sells: 6

Quarterly Holders Quick Answers

What is CUSIP 04962H506?
CUSIP 04962H506 identifies ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2019
Previous quarter: Q1 2019

Recent filing periods for CUSIP 04962H506:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ATOS - ATOSSA THERAPEUTICS, INC. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
VANGUARD GROUP INC	13F	Company	0.05%	69,489	$245,000	—	31 Mar 2019	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.04%	47,372	$166,000	—	31 Mar 2019	13F
Virtu Financial LLC	13F	Company	0.03%	36,310	$128,000	—	31 Mar 2019	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.02%	26,200	$92,000	—	31 Mar 2019	13F
Federation Des Caisses Desjardins du Quebec	13F	Individual	0.01%	18,000	$63,360	—	31 Mar 2019	13F
Ahrens Investment Partners LLC	13F	Company	0.08%	100,000	$35,000	—	31 Mar 2019	13F
BARCLAYS PLC	13F	Company	0.01%	7,184	$25,000	—	31 Mar 2019	13F
MORGAN STANLEY	13F	Company	0%	2,383	$8,000	—	31 Mar 2019	13F
BlackRock Finance, Inc.	13F	Company	0%	617	$2,000	—	31 Mar 2019	13F
Parallax Volatility Advisers, L.P.	13F	Company	0%	209	$1,000	—	31 Mar 2019	13F

Institutional Holders of ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) as of Q2 2019

As of 30 Jun 2019, ATOSSA THERAPEUTICS, INC. - Common Stock (ATOS) was held by 8 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 253,600 shares. The largest 8 holders included VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Federation des caisses Desjardins du Quebec, CITADEL ADVISORS LLC, Ahrens Investment Partners LLC, BARCLAYS PLC, Tower Research Capital LLC (TRC), and MORGAN STANLEY. This page lists 8 institutional shareholders reporting positions in this security for the Q2 2019 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2019 vs Q1 2019 Across Filers

Q1 2019 holders

Q2 2019 holders

Holder diff

-1

Investor	Q1 2019 Shares	Q2 2019 Shares	Share Diff	Share Chg %	Q1 2019 Value $	Q2 2019 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.